Literature DB >> 25432871

[Therapeutic relevance of HRCT findings from a pneumological viewpoint].

R Suchy1, M Pfeifer.   

Abstract

The high-resolution computed tomography (HRCT) technique is an essential component in diagnosing interstitial lung disease (ILD) as it provides important and specialized information and a much greater accuracy than chest X-rays. It contributes to a narrowing down of the differential diagnoses and is also important for planning further invasive investigations, e.g. bronchoscopy, bronchoalveolar lavage, transbronchial lung biopsy and surgical lung biopsy, if needed. An accurate diagnosis of ILD is based on a multidisciplinary discussion involving pulmonologists, radiologists and pathologists experienced in the diagnosis of ILD.The therapy approaches of five different entities of ILD are shown as examples. In hypersensitivity pneumonitis the mainstay of treatment is complete avoidance of exposure to the provoking antigen. In cryptogenic organizing pneumonia most patients recover with corticosteroid therapy with prednisolone over a period of 6 months to 1 year. In cases of sarcoidosis therapy depends on organ involvement and functional impairment but there is no durable benefit to routine treatment of patients with acute pulmonary sarcoidosis, even among those with stage II or III chest radiographs. In general, patients with severe or progressive disease will require treatment.In idiopathic pulmonary fibrosis (IPF) a confident radiological diagnosis of definitive usual interstitial pneumonia (UIP) obviates the need for surgical lung biopsy. Other etiologies of a HRCT pattern of UIP, such as domestic and occupational environmental exposure, connective tissue disease and drug toxicity must be ruled out. In IPF antifibrotic therapy with pirfenidone (approval since 2011) or the triple tyrosine kinase inhibitor nintendanib (pending approval in 2015) can reduce disease progression but therapy with acetylcysteine alone or in combination with prednisolone and azathioprine failed to meet efficacy endpoints. In the management of scleroderma associated ILD rapid semiquantitative evaluation of the extent of the disease on HRCT > 20% is useful for identifying patients who require treatment.

Entities:  

Mesh:

Year:  2014        PMID: 25432871     DOI: 10.1007/s00117-014-2739-y

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  16 in total

1.  The clinical impact of high resolution computed tomography in patients with respiratory disease.

Authors:  Nicholas J Screaton; Fiona N A C Miller; Bipen D Patel; Ashley Groves; Angela D Tasker; David A Lomas; Christopher D R Flower
Journal:  Eur Radiol       Date:  2010-08-24       Impact factor: 5.315

2.  Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis.

Authors:  Shinichiro Ohshimo; Francesco Bonella; Ai Cui; Martin Beume; Nobuoki Kohno; Josune Guzman; Ulrich Costabel
Journal:  Am J Respir Crit Care Med       Date:  2009-02-26       Impact factor: 21.405

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

4.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Authors:  Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2011-05-13       Impact factor: 79.321

5.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin J Anstrom; Talmadge E King; Joseph A Lasky; Fernando J Martinez
Journal:  N Engl J Med       Date:  2012-05-20       Impact factor: 91.245

Review 6.  Treatment of sarcoidosis.

Authors:  Catherine A Lazar; Daniel A Culver
Journal:  Semin Respir Crit Care Med       Date:  2010-07-27       Impact factor: 3.119

7.  [German guideline for diagnosis and management of idiopathic pulmonary fibrosis].

Authors:  J Behr; A Günther; W Ammenwerth; I Bittmann; R Bonnet; R Buhl; O Eickelberg; R Ewert; S Gläser; J Gottlieb; C Grohé; M Kreuter; C Kroegel; P Markart; C Neurohr; M Pfeifer; A Prasse; N Schönfeld; J Schreiber; H Sitter; D Theegarten; A Theile; A Wilke; H Wirtz; C Witt; H Worth; P Zabel; J Müller-Quernheim; U Costabel
Journal:  Pneumologie       Date:  2013-01-16

8.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

9.  Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.

Authors:  Fernando J Martinez; Joao A de Andrade; Kevin J Anstrom; Talmadge E King; Ganesh Raghu
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.